These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 807089)

  • 1. Dopaminergic agonists in animal models of parkinsonism.
    Poirier LJ
    Adv Neurol; 1975; 9():327-35. PubMed ID: 807089
    [No Abstract]   [Full Text] [Related]  

  • 2. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions.
    Murer MG; Dziewczapolski G; Menalled LB; García MC; Agid Y; Gershanik O; Raisman-Vozari R
    Ann Neurol; 1998 May; 43(5):561-75. PubMed ID: 9585350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of behavioural effects of a selective NMDA NR1A/2B receptor antagonist in the unilateral 6-OHDA lesion rat model.
    Warraich ST; Allbutt HN; Billing R; Radford J; Coster MJ; Kassiou M; Henderson JM
    Brain Res Bull; 2009 Feb; 78(2-3):85-90. PubMed ID: 18822357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levodopa in the treatment of Parkinson's disease: current controversies.
    Gerlach M; Reichmann H; Riederer P
    Mov Disord; 2005 May; 20(5):643; author reply 643-4. PubMed ID: 15732130
    [No Abstract]   [Full Text] [Related]  

  • 5. Functional MRI of basal ganglia responsiveness to levodopa in parkinsonian rhesus monkeys.
    Chen Q; Andersen AH; Zhang Z; Ovadia A; Cass WA; Gash DM; Avison MJ
    Exp Neurol; 1999 Jul; 158(1):63-75. PubMed ID: 10448418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Behavioral, physiological, and neurochemical changes after 6-hydroxydopamine-induced degeneration of the nigro-striatal dopamine neurons.
    Ungerstedt U; Ljungberg T; Steg G
    Adv Neurol; 1974; 5():421-6. PubMed ID: 4531217
    [No Abstract]   [Full Text] [Related]  

  • 7. Experimental neuropathy with Parkinson-like muscular rigidity. A suitable model for testing dopaminergic agonists and neuroleptic drugs.
    Halbhübner K; Herken H; Loos D
    Arzneimittelforschung; 1978; 28(10):1743-52. PubMed ID: 39569
    [No Abstract]   [Full Text] [Related]  

  • 8. Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease.
    Greenamyre JT; Eller RV; Zhang Z; Ovadia A; Kurlan R; Gash DM
    Ann Neurol; 1994 Jun; 35(6):655-61. PubMed ID: 8210221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between animal models and clinical parkinsonism.
    Marsden CD; Duvoisin RC; Jenner P; Parkes JD; Pycock C; Tarsy D
    Adv Neurol; 1975; 9():165-75. PubMed ID: 1146651
    [No Abstract]   [Full Text] [Related]  

  • 10. The effect of anti-Parkinson drugs on catalepsy induced by -methyl-p-tyrosine in rats pretreated with intraventricular 6-hydroxydopamine.
    Cashin CH; Sutton S
    Br J Pharmacol; 1973 Mar; 47(3):658P-659P. PubMed ID: 4738385
    [No Abstract]   [Full Text] [Related]  

  • 11. [Treatment of patients with vascular parkinsonism with the preparations nakom and madopar].
    Kamenetskiĭ VK
    Klin Med (Mosk); 1984 Apr; 62(4):112-6. PubMed ID: 6737958
    [No Abstract]   [Full Text] [Related]  

  • 12. Behavioural effects of a selective NMDA NR1A/2B receptor antagonist in rats with unilateral 6-OHDA+parafascicular lesions.
    Truong L; Allbutt HN; Coster MJ; Kassiou M; Henderson JM
    Brain Res Bull; 2009 Feb; 78(2-3):91-6. PubMed ID: 19007866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New directions in contemporary pharmacotherapy of parkinsonism (review)].
    Kurako IuL; Volianskiĭ VE
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1984; 84(9):1401-6. PubMed ID: 6150591
    [No Abstract]   [Full Text] [Related]  

  • 14. Biochemical aspects of experimentally induced parkinsonism.
    Goldstein M; Anagnoste B; Battista AF; Nakatani S; Ogawa M
    Res Publ Assoc Res Nerv Ment Dis; 1972; 50():434-47. PubMed ID: 4403657
    [No Abstract]   [Full Text] [Related]  

  • 15. Update on Parkinson disease.
    Lieberman AN
    N Y State J Med; 1987 Mar; 87(3):147-53. PubMed ID: 3472111
    [No Abstract]   [Full Text] [Related]  

  • 16. [Therapy of Parkinson syndrome].
    Clarenbach P; Fröscher W
    Fortschr Med; 1986 Nov; 104(44):857-61. PubMed ID: 3804157
    [No Abstract]   [Full Text] [Related]  

  • 17. Glial cell line-derived neurotrophic factor-levodopa interactions and reduction of side effects in parkinsonian monkeys.
    Miyoshi Y; Zhang Z; Ovadia A; Lapchak PA; Collins F; Hilt D; Lebel C; Kryscio R; Gash DM
    Ann Neurol; 1997 Aug; 42(2):208-14. PubMed ID: 9266731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular parkinsonism--an important update.
    Turnbull C
    Age Ageing; 2005 Mar; 34(2):97-8. PubMed ID: 15713851
    [No Abstract]   [Full Text] [Related]  

  • 19. Drug-induced parkinsonism in schizophrenic patients: motor response and psychiatric changes after acute challenge with L-Dopa and apomorphine.
    Merello M; Starkstein S; Petracca G; Cataneo EA; Manes F; Leiguarda R
    Clin Neuropharmacol; 1996 Oct; 19(5):439-43. PubMed ID: 8889287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apomorphine and levodopa challenge in patients with a focal midbrain lesion.
    Moro E; Albanese A
    Mov Disord; 1999 Mar; 14(2):269-75. PubMed ID: 10091621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.